知镜 Cognispect · 医学文献与研究工作台

HIF-2α in Lung Biology and Disease: From Adaptation and Repair to Therapeutic Modulation.

Man HJ, Saha AD, Wu L, de Perrot M.
Biology · 2026-10-22 · PMID 43026918

文献摘要

Hypoxia-inducible factor 2α (HIF-2α), encoded by EPAS1 , has long been studied in erythropoiesis, high-altitude adaptation, and cancer. Recent studies also implicate HIF-2α within non-malignant lung development and disease. This review examines HIF-2α as a dosage-sensitive, context-dependent regulator of lung cell state rather than a uniformly protective or pathogenic transcription factor. HIF-2α inhibitors have been approved in oncology, while pulmonary studies demonstrate roles for HIF-2α in fetal lung maturation, endothelial barrier integrity, alveolar-capillary maintenance, pulmonary vascular remodeling, aberrant epithelial repair, fibroblast persistence, airway differentiation, and alveolar macrophage metabolic and surfactant homeostasis. We summarize the canonical EGLN /PHD-VHL-HIF pathway, the HIF-1α/HIF-2α isoform bias, human genetic evidence from chronic hypoxia adaptation, and emerging disease-specific data in pulmonary arterial hypertension, pulmonary fibrosis, COPD/emphysema, acute lung injury/ARDS, and muco-obstructive disease. We also highlight chromatin, long noncoding RNA, and post-transcriptional mechanisms that tune HIF-2α activity. Together, these findings support the need to precisely tailor HIF-2α modulation in lung disease, guided by cell type, disease phase, spatial context, and biological objective.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。